Inauguration of CMA Terminals Khalifa Port Boosts the Port’s Total Container Capacity by 23% to almost 10m TEUs
12.12.2024 18:19:00 CET | Business Wire | Press release
With the new CMA CGM Terminal, Khalifa Port becomes the regional hub headquarters for three of world’s top five shipping companiesCMA Terminals Khalifa Port will play a vital role in enhancing UAE inland and maritime connectivityThe sustainably designed container terminal is operated under a 35-year concession by a joint venture between CMA CGM & AD Ports GroupThe completed phase 1 of CMA Terminals Khalifa Port cost AED 3.1 billion (USD 845 million), and adds 1.8 million TEUs capacity to Khalifa Port
AD Ports Group (ADPORTS:ADX), an enabler of integrated trade, transport and logistics solutions, announced the inauguration of CMA Terminals Khalifa Port, a state-of-the-art, AED 3.1 billion (USD 845 million) container terminal by His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212510462/en/

HH Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Rodolphe Saadè, Captain Mohamed Al Shamisi during the inauguration of CMA Terminals Khalifa Port (Photo: AETOSWire)
The inauguration is a major milestone in the development of Khalifa Port, AD Ports Group’s flagship port. The world-class container, ro-ro, and multipurpose port facility opened in December 2012, and in just 12 years has expanded to become one of the world’s fastest-growing, most efficient commercial ports.
CMA Terminals Khalifa Port, managed by a joint venture between the CMA CGM Group’s subsidiary CMA Terminals (70%) and AD Ports Group (30%), showcases advanced port infrastructure, including automated gates and integrated systems that enhance efficiency and sustainability. The facility offers shore-power for vessels to limit emissions, several solar panels areas contributing to the energy mix of the terminal operations and includes the region’s first net zero carbon administration building, which is powered by renewable energy sources. The building won the Net Zero Building Project of the Year Award in 2022 from the MENA Green Building Awards.
The addition of the CMA CGM facility increases Khalifa Port’s annual container capacity by 23% to almost 10 million TEUs (Twenty Foot Equivalent Units). The new terminal is ready for rail connectivity and will significantly enhance Khalifa Port’s position as a major gateway for the region. The design of the new facility incorporates sustainability principles into the construction which support the UAE’s wider targets for building the circular economy, recycling construction and reducing operational waste.
The new facility includes eight advanced Ship to Shore (STS) cranes, and 20 Electric Rubber Tyred Gantry (e-RTG) cranes, which enhances Khalifa Port’s reputation as one of the world’s most technologically advanced commercial ports, underscoring Abu Dhabi’s role in driving the future of sustainable and smart trade.
H.E. Mohamed Hassan Alsuwaidi, Chairman of AD Ports Group, said: “The inauguration of CMA Terminals Khalifa Port highlights the UAE as a premier investment destination and solidifies its position as a key partner for global players. The new terminal will boost trade flows and foster long-term economic growth in Abu Dhabi and the UAE.”
Rodolphe Saadé, Chairman and Chief Executive Officer of the CMA CGM Group, said: “The inauguration of our new container terminal is a major step in the development of Khalifa Port, consolidating Abu Dhabi's position as a global trade hub. This strategic infrastructure will boost shipping and logistics activities across the region. Together with our partner AD Ports Group, we are pleased to deliver a modern terminal with a strong focus on innovation and sustainability.”
Captain Mohamed Juma Al Shamisi, Managing Director and Group CEO, AD Ports Group, said: “CMA Terminals Khalifa Port will significantly boost Abu Dhabi’s connectivity, reinforcing its vital role on the global trade map and contributing to local economic diversification in line with the vision of our leadership. This new facility places AD Ports Group firmly in the ranks of the world’s leading global port operators. We look forward to a long, mutually beneficial partnership with CMA CGM that brings long-term economic benefits to the UAE and Abu Dhabi, as we work together to build a sustainable global transport future.”
The inauguration of CMA Terminals Khalifa Port marks the completion of Phase 1 of the new terminal project for CMA CGM, with the opening of an initial quay wall of 800 metres 18.5 metres of depth, and 8 STS Cranes adding a total capacity of 1.8 million TEUs (Twenty Foot Equivalent Units) to Khalifa Port.
With the opening of the new CMA CGM facility, Khalifa Port has reached a new stage as one of the region’s leading port trade hubs. Khalifa Port now extends over 6.3 km2, with 41 quay cranes, 159 yard cranes, 11.7 km of quay wall and 3.8 km of breakwater length.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20241212510462/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom